Table 1.
Summary of retrospective studies evaluating the role of salvage chemotherapy after anti-PD-1 treatment in R/M head and neck cancer.
| Study reference | N | ORR | PFS | OS |
|---|---|---|---|---|
| Koyama T. et al., 2024 (11) | 35 | 69.6% | 5.5 months | 13.3 months |
| Tanaka H. et al., 2023 (12) | 59 | 62.7% | 4.6 months | 17.1 months |
| Wakasaki T. et al., 2022 (13) | 52 | 53% | 7.4 months | 11.9 months |
| Cabezas S. et al., 2021 (14) | 23 | 56.5% | 6 months | 12 months |
| Kurosaki T. et al., 2021 (15) | 22 | 40.9% | 5.2 months | 14.5 months |
| Suzuki S. et al., 2020 (16) | 18 | 44.4% | 3.8 months | 9.6 months |
| Kacew A. et al., 2020 (17) | 60 | 27% | 3.3 months | 9.8 months |
| Pestana R. et al., 2020 (18) | 43 | 42% | 4.2 months | 8.4 months |
| Ueki Y. et al., 2020 (19) | 21 | 52.4% | 5.4 months | 12.9 months |
| Saleh K. et al., 2019 (20) | 82 | 53% | 3.6 months | 7.8 months |
N, number of patients included; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; m, months